The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
ThomasX., ArchimbaudE.Mitoxantrone in the treatment of acute myelogenous leukemia: A review.Hematol Cell Ther.1997; 39: 163–74.
2.
AmadoriS., ArceseW., IsacchiG.Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.J Clin Oncol.1991; 9: 1210–4.
3.
VisaniG., PettiM.C., CenacchiA.MEC (mitoxantrone, etoposide, and intermediate dose cytarabine): An effective induction regimen for previously untreated acute non-lymphocytic leukemia.Leuk Lymphoma.1995; 19: 447–51.
4.
TallmanM.S., LeeS., SikicB.I.Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia.Cancer.1999; 85: 358–67.
5.
ArchimbaudE., ThomasX., LeblondV.Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone, and cytarabine—86 trial.J Clin Oncol.1995; 13: 11–8.
6.
ArchimbaudE., JehnU., ThomasX.Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.Leukemia.1999; 13: 843–9.
7.
TribaltoM., CantonettiM., CatalanoG.Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients.Haematologica.1991; 76: 402–5.
8.
ShepherdJ.D., ReeceD.E., BarnettM.J.Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone, and etoposide.Leuk Lymphoma.1993; 9: 211–5.
9.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15: 103–9.
10.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
11.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM version].Rockledge, PA: National Comprehensive Cancer Network; 2001.
12.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17: 2971–94.
13.
RazisE., ArlinZ.A., AhmedT.Incidence and treatment of tumor lysis syndrome in patients with acute leukemia.Acta Haematol.1994; 91: 171–4.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18: 3558–85.
16.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35: 57–9, 63–7,70–4.
17.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function.Cancer Treat Rev.1995; 21: 33–64.
18.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24: 969–90.
